{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:47:11Z","timestamp":1791319631426,"version":"4.3.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"The Cridlan Trust"},{"name":"The Royal Marsden NIHR Biomedical Research Centre"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.breast.2015.09.008","type":"journal-article","created":{"date-parts":[[2015,10,18]],"date-time":"2015-10-18T03:06:52Z","timestamp":1445137612000},"page":"751-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab"],"prefix":"10.1016","volume":"24","author":[{"given":"B.","family":"Yeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kotsori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2015.09.008_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2015.09.008_bib2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2015.09.008_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2015.09.008_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/030089160709300514","article-title":"When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?","volume":"93","author":"Beda","year":"2007","journal-title":"Tumori"},{"key":"10.1016\/j.breast.2015.09.008_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/1752-1947-4-401","article-title":"Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report","volume":"4","author":"Syrios","year":"2010","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.breast.2015.09.008_bib6","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/annonc\/mds221","article-title":"Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer","volume":"23","author":"Gullo","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2015.09.008_bib7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1186\/1471-2407-14-806","article-title":"Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer \u2013 results from the HER-OS patient registry","volume":"14","author":"Witzel","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2015.09.008_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1634\/theoncologist.2012-0448","article-title":"Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study","volume":"18","author":"Swain","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2015.09.008_bib9","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/cncr.25771","article-title":"Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study","volume":"117","author":"Musolino","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2015.09.008_bib10","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-10-2962","article-title":"Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER","volume":"17","author":"Brufsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2015.09.008_bib11","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1200\/JCO.2013.54.0955","article-title":"Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: american society of clinical oncology clinical practice guideline","volume":"32","author":"Ramakrishna","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2015.09.008_bib12","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","article-title":"Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience","volume":"24","author":"Guarneri","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2015.09.008_bib13","article-title":"Trastuzumab-containing regimens for metastatic breast cancer","volume":"6","author":"Balduzzi","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097761500209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097761500209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:34:19Z","timestamp":1760776459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097761500209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S096097761500209X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2015.09.008","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2015.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}